Skip to main content

Advertisement

SpringerLink
Log in

Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Women in POSSIBLE US™ who expressed greater treatment satisfaction at study entry were more likely to persist with osteoporosis therapy over a 1-year period. Lower satisfaction among women with moderate/severe side effects increased the risk of discontinuation/switching by 67%. Treatment satisfaction and side effect experience influence osteoporosis medication adherence.

Introduction

Non-adherence is common among women using postmenopausal osteoporosis (PMO) medications. We describe the association between treatment satisfaction, measured with the Treatment Satisfaction Questionnaire for Medication (TSQM), and the risk of discontinuation/switching PMO medications using patient-reported data from a large, longitudinal cohort study.

Methods

Data from 2,405 participants in the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US™) Study were evaluated. Cox proportional hazards regression was used to estimate hazard ratios (HR) for the association between treatment satisfaction at study entry and self-reported discontinuation/switching of pharmacologic PMO medications over a 1-year follow-up period. Logistic regression was used to evaluate relationships between treatment satisfaction, lifestyle behaviors, and compliance with bisphosphonate dosing instructions.

Results

Median TSQM scores were highest (indicating greatest satisfaction) for the side effects domain [n = 1,182; median = 87.5 (Q1 = 75.0, Q3 = 100.0)] and lowest for global satisfaction [n = 2,340; median = 64.0 (Q1 = 55.7, Q3 = 77.7)]. Median scores decreased for the side effects and global satisfaction domains as patient-reported side effect severity increased. Women with higher satisfaction were less likely to discontinue/switch medications than women with lower scores (adjusted HRs for convenience 0.73, 95% CI = 0.63–0.85; effectiveness 0.82, 95% CI = 0.70–0.97; and global satisfaction 0.73, 95% CI = 0.63–0.85). Lower treatment satisfaction was particularly influential among women who reported moderate/severe side effects (HR = 0.60, 95% CI = 0.37–0.97).

Conclusions

Lower treatment satisfaction was associated with a 22% (1/0.82) to 67% (1/0.60) increased risk of discontinuation/switching osteoporosis medication during 1 year of follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville, MD

  2. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501

    Article  PubMed  Google Scholar 

  3. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951

    Article  PubMed  CAS  Google Scholar 

  4. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216

    Article  PubMed  Google Scholar 

  5. Pickney CS, Arnason JA (2005) Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 16:1156–1160

    Article  PubMed  Google Scholar 

  6. Burgener M, Arnold M, Katz JN, Polinski JM, Cabral D, Avorn J, Solomon DH (2005) Older adults’ knowledge and beliefs about osteoporosis: results of semistructured interviews used for the development of educational materials. J Rheumatol 32:673–677

    PubMed  Google Scholar 

  7. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice (TOP) Study Group (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921

    Article  PubMed  CAS  Google Scholar 

  8. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259–262

    PubMed  CAS  Google Scholar 

  9. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871–1886

    Article  PubMed  CAS  Google Scholar 

  10. Kendler D, Kung AW, Gel-H F, González González JG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243–251

    Article  PubMed  CAS  Google Scholar 

  11. Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shaloms S (2005) Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 17:143–149

    PubMed  CAS  Google Scholar 

  12. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861

    Article  PubMed  Google Scholar 

  13. Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43–49

    Article  PubMed  CAS  Google Scholar 

  14. Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38:S2–S6

    Article  PubMed  CAS  Google Scholar 

  15. Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205–210

    Article  PubMed  CAS  Google Scholar 

  16. Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383–2391

    Article  PubMed  CAS  Google Scholar 

  17. Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM (2006) An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord 90:217–221

    Article  PubMed  Google Scholar 

  18. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644

    Article  PubMed  CAS  Google Scholar 

  19. Shikiar R, Rentz AM (2004) Satisfaction with medication: an overview of conceptual, methodological, and regulatory issues. Value Health 7:204–215

    Article  PubMed  Google Scholar 

  20. Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA (2009) Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. South Med J 102:486–492

    Article  PubMed  Google Scholar 

  21. Barrett-Connor E, Ensrud K, Tosteson ANA, Varon SF, Anthony M, Daizadeh N, Wade S (2009) Design of the POSSIBLE USTM Study: postmenopausal women’s compliance and persistence with osteoporosis medications. Osteoporos Int 20:463–472

    Article  PubMed  CAS  Google Scholar 

  22. Tosteson ANA, Do T, Wade S, Anthony M, Downs R (2010) Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™. Osteoporos Int 21:1769–1780

    Article  PubMed  CAS  Google Scholar 

  23. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12

    Article  PubMed  Google Scholar 

  24. Centers for Disease Control and Prevention. About BMI for Adults. http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html 7/27/09. Accessed 6 September 2010

  25. Cook PF, Emiliozzi S, McCabe MM (2007) Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 22:445–456

    Article  PubMed  Google Scholar 

  26. McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23(12):3137–3152

    Article  PubMed  CAS  Google Scholar 

  27. Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23(11):1815–1821

    Article  PubMed  Google Scholar 

  28. Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Pyschomatic Res 47(6):555–567

    Article  CAS  Google Scholar 

  29. Horne R, Weinman J (2002) Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatments beliefs in explaining non-adherence to preventer medication. Psychol Health 17:17–32

    Article  Google Scholar 

  30. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K (2003) Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt) 12:1037–1045

    Article  CAS  Google Scholar 

  31. Pencille LJ, Campbell ME, Van Houten HK, Shah ND, Mullan RJ, Swiglo BA, Breslin M, Kesman RL, Tulledge-Scheitel SM, Jaeger TM, Johnson RE, Bartel GA, Wermers RA, Melton LJ 3rd, Montori VM (2009) Protocol for osteoporosis choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials 10:113

    Article  PubMed  Google Scholar 

  32. Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R (2009) Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt) 18:935–943

    Article  Google Scholar 

  33. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized crossover study (BALTO II). Joint Bone Spine 75:303–310

    Article  PubMed  CAS  Google Scholar 

  34. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903

    Article  PubMed  CAS  Google Scholar 

  35. Payer J, Killinger Z, Sulková I, Celec P (2008) Preferences of patients receiving bisphosphonates—how to influence the therapeutic adherence. Biomed Pharmacother 62:122–124

    Article  PubMed  CAS  Google Scholar 

  36. Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, Borenstein J, Wang H, Man HS, Wagman RB, Siddhanti S, Macarios D, Bone HG (2010) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837–846

    Article  PubMed  CAS  Google Scholar 

  37. Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20(12):2127–2134

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to acknowledge the other members of the POSSIBLE US™ Steering Committee: Robert Downs, Ted Ganiats, Marc Hochberg, Barbara Lukert, Robert Recker, Robert Rubin and Anna Tosteson. We would also like to acknowledge the REGISTRAT, Inc. staff members who assisted with the implementation of this study and ongoing data collection, as well as Sue Hudson, who provided editorial assistance on behalf of Amgen Inc. Funding for this study was provided by Amgen Inc., Thousand Oaks, CA USA.

Conflicts of interest

E. Barrett-Connor receives support from Amgen, Inc. for serving as Chair of the POSSIBLE US™ Study Steering Committee; she is an investigator on clinical trials for Arena Pharmaceuticals, Boehringer Ingelheim, Merck, Pfizer and Roche. Dr. Barrett-Connor also receives grant funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research Resources (NCRR), and NIH Roadmap for Medical Research. S. Wade and S. Satram-Hoang provide consulting services to Amgen Inc. T. P. Do, R. Stewart, G. Gao, and D. Macarios are employees of Amgen Inc. and have received Amgen stock/stock options.

Author information

Authors and Affiliations

  1. Division of Epidemiology, Department of Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0607, USA

    E. Barrett-Connor

  2. Wade Outcomes Research and Consulting, Salt Lake City, UT, USA

    S. W. Wade

  3. Amgen Inc., Thousand Oaks, CA, USA

    T. P. Do, S. Satram-Hoang, R. Stewart, G. Gao & D. Macarios

Authors
  1. E. Barrett-Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. W. Wade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. P. Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Satram-Hoang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Macarios
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Barrett-Connor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barrett-Connor, E., Wade, S.W., Do, T.P. et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporos Int 23, 733–741 (2012). https://doi.org/10.1007/s00198-011-1620-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1620-3

Keywords

Search

Navigation